



# Understanding DEA Regulations and FDA Interactions: A Case Study on Opioids

**Larry K. Houck**, Director, Hyman, Phelps & McNamara, PC

**Lynn Mehler**, Partner, Hogan Lovells US LLP

**Loren Miller**, Policy Section Chief, Diversion Control  
Division, DEA

**DEA**

U.S. DRUG ENFORCEMENT ADMINISTRATION



# Food and Drug Law Institute

Loren Miller, Section Chief

Policy Section

Diversion Control Division







# LEGAL DISCLAIMER

The following presentation was accompanied by an oral presentation on **May 3, 2019**, and does not purport to establish legal standards that are not contained in statutes, regulations, or other competent law. Statements contained in this presentation that are not embodied in the law are not binding on DEA. Summaries of statutory and regulatory provisions that are summarized in this presentation do not purport to state the full extent of the statutory and regulatory requirements of the cited statutes and regulations. **I have no financial relationships to disclose.**

# Closed System of Distribution



# Closed System of Distribution





# The Registrant Community

- Total number of DEA registrants: **1,805,073**
- Total number of Practitioners and MLP: **1,696,971**
- Total number of Pharmacies: 71,338
- Total number of Hospitals: 18,289
- Total number of Distributors 708
- Total number of Manufacturers 584



# Understanding DEA Regulations and FDA Interactions: A Case Study on Opioids

**Larry K. Houck**, Director, Hyman, Phelps & McNamara, PC

**Lynn Mehler**, Partner, Hogan Lovells US LLP

**Loren Miller**, Policy Section Chief, Diversion Control  
Division, DEA